Upregulation of α3β1-Integrin in Podocytes in Early-Stage Diabetic Nephropathy

Kaichiro Sawada, Masao Toyoda, Noriko Kaneyama, Sawako Shiraiwa, Hitomi Moriya, Han Miyatake, Eitaro Tanaka, Naoyuki Yamamoto, Masaaki Miyauchi, Moritsugu Kimura, Takehiko Wada, and Masafumi Fukagawa

Division of Nephrology, Endocrinology and Metabolism, Department of Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan

Correspondence should be addressed to Masao Toyoda; m-toyoda@is.icc.u-tokai.ac.jp

Received 6 April 2016; Accepted 5 May 2016

Background. Podocyte injury plays an important role in the onset and progression of diabetic nephropathy (DN). Downregulation of α3β1-integrin expression in podocytes is thought to be associated with podocyte detachment from the glomerular basement membrane, although the mechanisms remain obscure. To determine the mechanism of podocyte detachment, we analyzed the expression levels of α3β1-integrin in podocytes in early and advanced stages of DN. Methods. Surgical specimens from DN patients were examined by in situ hybridization, and the expression levels of α3- and β1-integrin subunits in glomeruli of early (n = 6) and advanced (n = 8) stages were compared with those of normal glomeruli (n = 5). Heat-sensitive mouse podocytes (HSMP) were cultured with TGF-β1 to reproduce the microenvironment of glomeruli of DN, and the expression levels of integrin subunits and the properties of migration and attachment were examined. Results. Podocytes of early-stage DN showed upregulation of α3β1-integrin expression while those of advanced stage showed downregulation. Real-time PCR indicated a tendency for upregulation of α3- and β1-integrin in HSMP cultured with TGF-β1. TGF-β1-stimulated HSMP also showed enhanced in vitro migration and attachment on collagen substrate. Conclusions. The results suggested that podocyte detachment during early stage of DN is mediated through upregulation of α3β1-integrin.

1. Introduction

Diabetic nephropathy (DN) is one of the major indications for hemodialysis treatment in patients with diabetes mellitus (DM). It is important to elucidate the cause of DN and develop more effective treatments based on the escalating medical costs and need for improvement of quality of life (QOL) of DN patients. Previous studies showed that the onset and progression of DN correlate with injury of glomerular epithelial cells (podocytes) [1–7]. Furthermore, effacement of foot process followed by podocyte detachment from the glomerular basement membrane (GBM) is known to result in proteinuria [8]. Among the many molecules that are known to be involved in cell-to-cell and cell-to-substrate attachment in glomeruli, α3β1-integrin is expressed primarily in podocytes and considered to play a critical role in the attachment of podocytes to the GBM [9, 10]. Several studies have so far examined changes in α3β1-integrin expression in podocytes in patients with various types of nephropathies and equivalent animal models [11–19]. The results of studies involving DN patients, animal models of DN, and in vitro culture of podocytes under high glucose conditions have so far demonstrated underexpression of α3-integrin subunit in podocytes and suggested that the main cause of podocyte detachment was a decrease in the number of α3β1-integrins on the surface of podocytes [20–23]. However, the mechanism responsible for the downregulation of α3β1-integrin during progression of DN remains obscure.

TGF-β1 is synthesized and secreted by glomerular mesangial cells (MC) in patients with nephropathy and animal models of glomerulonephritis [24]. The secreted TGF-β1 from MC stimulates podocyte to synthesize collagen type IV.
The upregulation of the data of previous studies [20–23], the results showed of heat-sensitive mouse podocytes (HSMP). Contrary to the expression levels of DN. We also reproduced the changes, including changes in glomeruli of patients with early and advanced stages of in vitro early-stage DN. The results were confirmed in vitro TGF-α/β/γ.

The present study was designed to determine the mechanism of podocyte detachment in DN. For this purpose, we examined the expression of α3- and β1-integrin subunits in glomeruli of patients with early and advanced stages of DN. We also reproduced the changes, including changes in the expression levels of α3β1-integrin in an in vitro culture of heat-sensitive mouse podocytes (HSMP). Contrary to the data of previous studies [20–23], the results showed upregulation of α3β1-integrin expression in podocytes in early-stage DN. The results were confirmed in vitro culture of TGF-β1-stimulated mouse podocytes.

### 2. Methods

#### 2.1. Subjects

Renal biopsy tissues of 14 patients with DN were used. The diagnosis of DN was confirmed by histopathological examination and the severity was classified into two grades: grade I (DN1 = 6 patients) reflected mild mesangial expansion and DN grade II (DN2 = 8 patients) represented moderate mesangial expansion. Control samples were obtained from uninvolved portions of surgically removed kidneys afflicted with malignancies (5 patients). After resection, the samples were embedded in optimal cutting temperature (OCT) compound (Tissue Tek; Miles, Elkhart, IN) and stored at −70°C until use. Blood and urine samples were collected from subjects immediately before renal biopsy. Serum creatinine, total protein, HbA1c, urinary protein, and creatinine clearance were measured using standard methods in our hospital (Table 1).

This study was reviewed and approved by the Institutional Review Board of Tokai University School of Medicine. All procedures were performed in accordance with the principles of the Declaration of Helsinki. Informed consents were obtained from all subjects.

#### 2.2. In Situ Hybridization

Oligonucleotide probes for mRNAs of human α3- and β1-integrin subunits were labeled using a digoxigenin (DIG) oligonucleotide tailing kit according to the standard protocol (Boehringer Mannheim, Mannheim, Germany). Free DIG was removed by ethanol precipitation and probes were dissolved in diethylpyrocarbonate-treated water.

In situ hybridization was performed according to a protocol developed in our laboratory with minor modifications. Briefly, sections of specimens were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) and then deproteinized with HCl and digested with proteinase K (Sigma Chemical, St. Louis, MO). Following a treatment with a hybridization buffer, specimens were hybridized overnight with a DIG-labeled oligonucleotide probe in the same buffer. After washing with a stringent condition, the DIG-labeled probe was detected immunohistochemically using a mouse monoclonal anti-DIG antibody (Boehringer Mannheim), horseradish peroxidase (HRP-) conjugated rabbit anti-mouse IgG antibody (Dako, Glostrup, Denmark), and HRP-conjugated swine anti-rabbit IgG antibody (Dako). The reaction was visualized with diaminobenzidine tetrahydrochloride in 0.05 M Tris-HCl, pH 7.6, and 0.03% H2O2. Sections were briefly counterstained with hematoxylin, rinsed, dehydrated, cleared in xylene, and mounted. Three independent investigators who were blinded to the results of histopathological classification counted the numbers of stained cells. The percentage of mRNA-positive cells relative to the total glomerular cells was determined.

#### 2.3. Cell Culture

HSMP were cultured with RPMI 1640 medium (Nissui Pharma, Tokyo, Japan) containing 10% fetal bovine serum, 50 U/mL penicillin, and 50 mg/mL streptomycin in 5% CO2, 95% air atmosphere. Cells proliferated at 33°C in the presence of 50 units/mL mouse recombinant IFN-γ (Aviva System Biology, San Diego, CA). For podocyte differentiation, cells between passages 10 and 13 were cultured at 37°C without IFN-γ for two weeks. Podocyte differentiation was confirmed by the expression of synaptopodin detected by quantitative real-time PCR. To set the conditions of microenvironment to mimic those of DN glomeruli, 1 ng/mL TGF-β1 (R&D Systems, Minneapolis, MN) was added to medium. The medium was replaced with a new one every other day.

#### 2.4. Attachment and Migration Assays

HSMP were differentiated as above, and 1 ng/mL TGF-β1 was added before three days of experiments. Cells were harvested by trypsinization, counted, and inoculated into plates as described below.

To measure the ability of attachment of differentiated HSMP to the substrate, 1 × 10⁴ cells per well were inoculated into 24-well plate coated with collagen type IV and incubated at 37°C. After 30-minute incubation, the plates were shaken to detach weakly binding cells, washed several times with PBS(−), refilled with culture medium, and incubated at 37°C in 5% CO2. The next day the cells were fixed with 4% paraformaldehyde and photographed. The number of cells in the view fields was counted.

To measure the ability of differentiated HSMP to migrate towards the substrate, the Oris Pro cell migration assay kit (Platypus Technology, Fitchburg, WI) was used. 4 × 10⁴

### Table 1: Baseline characteristics.

|                     | NHK (n = 5) | DN1 (n = 6) | DN2 (n = 8) |
|---------------------|------------|------------|------------|
| Gender (M/F)        | 4/1        | 4/2        | 6/2        |
| Age (years)         | 45 ± 10    | 44 ± 17    | 48 ± 12    |
| Serum creatinine (mg/dL) | 0.9 ± 0.2   | 0.7 ± 0.1  | 1.1 ± 0.3* |
| Total protein (g/dL) | 7.4 ± 0.8   | 6.9 ± 0.6  | 6.0 ± 1.6  |
| HbA1c (%)           | ND         | 8.7 ± 2.3  | 8.8 ± 2.9  |
| Urinary protein (g/day) | ND         | 0.22 ± 0.15| 1.95 ± 2.45* |
| Creatinine clearance (mL/min) | 97.0 ± 20.5 | 73.3 ± 26.0* |

Data are expressed as mean ± SD.  
* p < 0.05 versus DN.
ND: not determined.
cells per well were inoculated into 96-well plate coated with collagen type I supplied with the kit. After 24 hours, the cells were fixed with 4% paraformaldehyde and stained with hematoxylin. Absorbance of 600 nm light passed into the central detection zone was measured by spectrophotometry (Infinite F200PRO, TECAN, Männedorf, Switzerland).

2.5. Quantitative Real-Time Polymerase Chain Reaction. Differentiated HSMP were inoculated into wells of 48-well plate coated with collagen type IV with a rate of 1 × 10^6 per well and cultured with 1 ng/mL TGF-β1 at 37°C under 5% CO₂-95% air atmosphere. According to the time schedule, total RNAs were recovered from cells using the RNAqueous RNA purification kit (ThermoFisher, Waltham, MA) and converted to cDNA using SuperScript III First-Strand Synthesis System (ThermoFisher). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed with the cDNA, as described previously [29]. The reaction mixture was prepared as described in the instruction manual of the kit (TaqMan Gene Expression Assays; ThermoFisher) that also contained the primers and probes for mouse α3-integrin (assay ID: Mm00442910_m1), β1-integrin (assay ID: Mm01253230_m1), and 18S ribosomal RNA (rRNA), which was used as the endogenous control. PCR was performed on an ABI PRISM 7500 (ThermoFisher). Data were analyzed by the comparative Ct method, and the amounts of integrin mRNAs were expressed relative to that of 18S rRNA.

2.6. Statistical Analysis. Results are expressed as mean ± SD. Differences between two groups were assessed by Student’s t-test. Spearman’s correlation coefficient analysis was used to examine the relationship between parameters. p < 0.05 was considered statistically significant.

3. Results

3.1. Patient Characteristics. The clinical characteristics of the patients are shown in Table 1. Based on the degree of mesangial expansion, patients were categorized into the DN1 and DN2 groups, as described in Methods. Serum creatinine, urinary protein, and creatinine clearance worsened significantly during the course of DN in DN2 patients compared with DN1 patients.

3.2. Expression of Integrin Subunits Detected by In Situ Hybridization. Representative glomeruli stained for α3- and β1-integrin are shown in Figure 1 and the percentages of cells positive for these mRNAs are summarized in Table 2. Although the percentage of cells positive for each integrin subunit in glomeruli was not significantly different to those of NHK when data of all DN patients were analyzed, those of DN1 were significantly higher (Table 2). Particularly, the percentage of cells positive for β1-integrin mRNA was significantly higher in DN1 than NHK. Furthermore, the percentages of cells positive for α3- and β1-integrin subunits were both significantly lower in DN2. Further analysis showed strong correlation between percentages of cells positive for α3- and β1-integrin subunits (Figure 2), suggesting that the increase in the subunits resulted in the formation of α3β1-integrin on the podocyte surface.

3.3. Induction of α3- and β1-Integrin Expression in Cultured Mouse Podocytes. Next, we induced the expression of integrin subunits in DN1 glomeruli in cultured HSMP. To mimic the condition of DN glomerular microenvironment, the cultured cells were treated with 1 ng/mL TGF-β1 for three days and RNAs were recovered at various time points. Although the expression of α3-integrin gene decreased significantly at the onset of the experiment, it recovered after 48 hours of culture and finally reached about twice the expression level at baseline (0 hours) (Figure 3). On the other hand, the expression of β1-integrin gene increased steadily and reached more than three times the baseline expression level at 72 hrs (Figure 3). Thus, the expression levels of both integrins increased proportionally with culture duration in the presence of TGF-β1. These results demonstrated that induction of α3- and β1-integrin subunits in glomeruli of DN1 patients can be reproduced by HSMP cultured with TGF-β1. On the other hand, enhanced detachment of cells from substrate was not observed during the experiments, and TGF-β1 did not affect the number of cells under these conditions (data not shown).

3.4. TGF-β1 Enhances Substrate Attachment and Migration of HSMP. Finally, we examined the effects of TGF-β1-induced expression of α3β1-integrin on substrate attachment and cell migration. For substrate attachment, type IV collagen-coated plates were shaken and washed after 30 minutes of cell inoculation, and the number of remaining cells was counted in the presence or absence of TGF-β1. On the other hand, migration was measured by using a cell migration assay kit, in which the extent of migration was measured by absorbance of stained cells that entered the central clear space of the plates. TGF-β1 significantly enhanced HSMP attachment to type IV collagen (Figure 4) and their migration on type I collagen-coated plate (Figure 5). These results suggest the involvement of both processes in the increased expression of α3β1-integrin induced by TGF-β1.

4. Discussion

The main finding of the present study was upregulation of integrin expression in podocytes of patients with early DN and in HSMP cultured with TGF-β1.
Figure 1: *In situ* hybridization of α3- and β1-integrin subunits. Representative mRNA expression of integrin subunits in glomeruli of normal human kidney, early (DN1) and advanced (DN2) stages of DN. Integrin expression is colored by DAB (brown), and nuclei of cells are stained by hematoxylin (blue) (magnification, ×100).

Figure 2: Strong correlation between the expression levels of α3- and β1-integrin subunits in DN glomeruli of 14 DN patients. The percentages of cells positive for α3- and β1-integrin in glomeruli were examined by *in situ* hybridization.

Since no proliferation of mature podocytes is noted in the majority of nephropathies, including DN [30], integrin mRNA overexpression in podocytes, including higher percentage of integrin-positive cells in DN1 glomeruli, can be detected by *in situ* hybridization. Although several studies involving DN patients and animal models reported a decrease or no change in α3β1-integrin expression in podocytes, almost all of them assessed the expression of integrin in podocytes of proceeded stage of DN in patients and animals [20–23]. The present study also showed no significant change in α3- and β1-integrin expression when data of all DN patients were pooled together and compared with those of NHK (Table 2). On the other hand, separate analysis of data of patients with early stage (DN1) demonstrated significant upregulation of integrin, which could have been masked in previous studies. Interestingly, controversial results regarding the expression patterns of integrin in podocytes have been reported in various types of nephropathies and glomerulonephritis other than DN [11–19]. In general, proteinuria correlates with downregulation of integrin in podocytes in various nephropathies, although an increase or no change in integrin expression has been reported in some cases of early-stage nephropathy. For example, overexpression of glomerular α3-integrin was reported in a rat model of minimal-change nephropathy 10 days after injection of puromycin...
aminonucleoside (PAN) [17]. Furthermore, Baraldi et al. reported downregulation of α3-integrin in 6 patients with stage I-III membranous nephropathy [11], whereas Bains et al. reported little change in integrin expression in 18 patients with "early"- stage proteinuria [16] and Chen et al. used a rat model of streptozotocin-induced DN to report no change in α3-integrin expression within the first week followed by a decrease after 1–3 months [21].

The upregulated expression of integrin in DN1 podocytes probably represents increased turnover and reconstruction of adhesion structures responsible for cell-substrate interaction [16]. This argument is supported by the finding of enhanced attachment and migration of HSMP with upregulated integrin expression. The reconstruction of adhesion structures could be a mechanism to counteract increased instability of DN1 podocytes caused by the effacement of foot process.

In the present study, HSMP were cultured with TGF-β1 instead of high glucose concentrations to reproduce the microenvironment in DN glomeruli. Previous studies reported that high glucose concentrations in culture medium result in downregulation of α3-integrin expression in podocytes within 24 hours, although the induction of α3-integrin as observed in DN1 podocytes has not been reported [21, 22]. It is likely that hyperglycemia does not directly change integrin expression in the early stages of DN. On the other hand, TGF-β1 is produced abundantly in mesangial proliferative glomerulonephritis [24, 27, 28] and induces podocytes to synthesize collagen type IV, which contributes to the proliferation of GBM [25, 26]. Moreover, TGF-β1 induces MC to synthesize type I collagen and β1-integrin, which contribute to the proliferation of mesangial substrates [31]. These evidences suggest that TGF-β1, rather than hyperglycemia, is directly involved in the regulation of cell-substrate interaction of podocytes and MC in glomeruli.

TGF-β1 is also known to induce cell death in certain types of cells [32, 33]. Our results showed death of HSMP after their detachment from the substrate when they were
cultured with TGF-β1 at concentrations higher than that used in experiments of the present study (data not shown). Although upregulation of genes involved in cell death of podocytes cultured under high glucose concentrations was reported [34], some studies described maintaining cultured podocytes under high glucose concentrations as long as 1-2 weeks and even more than 6 months [35, 36]. These studies suggest that direct stimulation by high glucose concentration may not be sufficient to induce podocyte detachment. One can probably establish a culture system that allows the process of detachment and death of podocytes.

In conclusion, upregulation of α3β1-integrin expression was detected in early-stage DN, suggesting reconstruction of adhesion structures essential for cell-substrate interaction after effacement of foot process. HSMP cultured with TGF-β1 reproduced α3- and β1-integrin upregulation observed in DNI, and podocytes stimulated with TGF-β1 showed enhanced attachment and migration. Our in vitro culture system that mimics the onset and progression of DN can be used to elucidate the mechanism of podocyte detachment and to develop effective treatments for proteinuria.

Competing Interests

The authors declare no conflict of interests in relation to this paper.

Acknowledgments

The authors thank the Research Support Center, Tokai University School of Medicine, for their valuable technical assistance. This study was sponsored by the Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine (Grant no. 14F188139), Tokai University School of Medicine, Japan.

References

[1] G. Wolf, S. Chen, and F. N. Ziyadeh, “From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy,” *Diabetes*, vol. 54, no. 6, pp. 1626–1634, 2005.
[2] M. W. Steffes, D. Schmidt, R. McCrery, and J. M. Basgen, “Glomerular cell number in normal subjects and in type 1 diabetic patients,” *Kidney International*, vol. 59, no. 6, pp. 2104–2113, 2001.
[3] K. E. White, R. W. Bilous, S. M. Marshall et al., “Podocyte number in normotensive type 1 diabetic patients with albuminuria,” *Diabetes*, vol. 51, no. 10, pp. 3083–3089, 2002.
[4] T. B. Torbjörnsdotter, N. E. Perrin, G. A. Jaremko, and U. B. Berg, “ Widening of foot processes in normoalbuminuric adolescents with type 1 diabetes,” *Pediatric Nephrology*, vol. 20, no. 6, pp. 750–758, 2005.
[5] M. E. Pagtalunan, P. L. Miller, S. Jumping-Eagle et al., “Podocyte loss and progressive glomerular injury in type II diabetes,” *The Journal of Clinical Investigation*, vol. 99, no. 2, pp. 342–348, 1997.
[6] K. E. White and R. W. Bilous, “Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients,” *Nephrology Dialysis Transplantation*, vol. 19, pp. 1437–1440, 2004.
[7] M. Dalla Vestra, A. Masiero, A. M. Roiter, A. Saller, G. Crepaldi, and P. Fioretto, “Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes,” *Diabetes*, vol. 52, no. 4, pp. 1031–1035, 2003.
[8] M. Toyoda, B. Najafian, Y. Kim, M. L. Caramori, and M. Maurer, “Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy,” *Diabetes*, vol. 56, no. 8, pp. 2155–2160, 2007.
[9] F. G. Cosio, “Cell-matrix adhesion receptors: relevance to glomerular pathology,” *American Journal of Kidney Diseases*, vol. 20, no. 3, pp. 294–305, 1992.
[10] M. A. Rahilly and S. Fleming, “Differential expression of integrin alpha chains by renal epithelial cells,” *The Journal of Pathology*, vol. 167, no. 3, pp. 327–334, 1992.
[11] A. Baraldi, L. Furti, G. Zambruno, E. Rubbiani, G. Annessi, and E. Lusvarghi, “Very late activation-3 integrin is the dominant β3-integrin on the glomerular capillary wall: an immunofluorescence study in nephrotic syndrome,” *Nephron*, vol. 62, no. 4, pp. 382–388, 1992.
[12] S. Kagami, W. A. Border, E. Ruosldhiti, and N. A. Noble, “Coordinated expression of β1 integrins and transforming growth factor-β-induced matrix proteins in glomerulonephritis,” *Laboratory Investigation*, vol. 69, no. 1, pp. 68–76, 1993.
[13] A. Baraldi, G. Zambruno, L. Furti et al., “β1 and β3 integrin upregulation in rapidly progressive glomerulonephritis,” *Nephrology Dialysis Transplantation*, vol. 10, no. 7, pp. 1155–1161, 1995.
[14] E. Kemeny, M. J. Mihatsch, U. Dürmüller, and F. Gudat, “Podocytes loose their adhesive phenotype in focal segmental glomerulosclerosis,” *Clinical Nephrology*, vol. 43, no. 2, pp. 71–83, 1995.
[15] K. Shikata, H. Makino, S. Morioka et al., “Distribution of extracellular matrix receptors in various forms of glomerulonephritis,” *American Journal of Kidney Diseases*, vol. 25, no. 5, pp. 680–688, 1995.
[16] R. Bains, P. N. Furness, and D. R. Critchley, “A quantitative immunofluorescence study of glomerular cell adhesion proteins in proteinuric states,” *Jour nal of Pathology*, vol. 183, no. 3, pp. 272–280, 1997.
[17] W. E. Smoyer, P. Mundel, A. Gupta, and M. J. Welsh, “Podocyte α-actinin induction precedes foot process effacement in experimental nephrotic syndrome,” *American Journal of Physiology—Renal Physiology*, vol. 273, no. 1, pp. F150–F157, 1997.
[18] P. Luimula, N. Sandström, D. Novikov, and H. Holthöfer, “Podocyte-associated molecules in puromycin aminonucleoside nephrosis of the rat,” *Laboratory Investigation*, vol. 82, no. 6, pp. 713–718, 2002.
[19] T. Nakatsue, H. Koike, G. D. Han et al., “Nephrin and podocin dissociate at the onset of proteinuria in experimental membranous nephropathy,” *Kidney International*, vol. 67, no. 6, pp. 2239–2253, 2005.
[20] R. Regoli and M. Bendayan, “Alterations in the expression of the alpha(3)beta(1) integrin in certain membrane domains of the glomerular epithelial-cells (podocytes) in diabetes-mellitus,” *Diabetologia*, vol. 40, pp. 15–22, 1997.
[21] H.-C. Chen, C.-A. Chen, J.-Y. Guh, J.-M. Chang, S.-J. Shin, and Y.-H. Lai, “Altering expression of α3β1 integrin on podocytes of human and rats with diabetes,” *Life Sciences*, vol. 67, no. 19, pp. 2345–2353, 2000.
[22] P. V. Kitsiou, A. K. Tzinia, W. G. Stetler-Stevenson et al., “Glucose-induced changes in integrins and matrix-related functions in cultured human glomerular epithelial cells,” *American
[23] S. Lin, D. Li, J. Jia, Z. Zheng, Z. Jia, and W. Shang, "Spiro-
lactone ameliorates podocytic adhesive capacity via restoring
integrin $\alpha_3$ expression in streptozotocin-induced diabetic rats," *Journal of the Renin-Angiotensin-Aldosterone System*, vol. 11, no. 3, pp. 149–157, 2010.

[24] W. A. Border, N. A. Noble, T. Yamamoto et al., "Natural inhibitor
of transforming growth factor-\(\beta\) protects against scarring in
experimental kidney disease," *Nature*, vol. 360, no. 6402, pp.
361–364, 1992.

[25] M. C. Iglesias-de la Cruz, F. N. Ziyadeh, M. Isono et al., "Effects
of high glucose and TGF-\(\beta1\) on the expression of collagen IV
and vascular endothelial growth factor in mouse podocytes," *Kidney International*, vol. 62, no. 3, pp. 901–913, 2002.

[26] S. Chen, Y. Kasama, J. S. Lee, B. Jim, M. Marin, and F. N.
Ziyadeh, "Podocyte-derived vascular endothelial growth factor
mediates the stimulation of $\alpha3(IV)$ collagen production by
transforming growth factor-\(\beta1\) in mouse podocytes," *Diabetes*,
vol. 53, no. 11, pp. 2939–2949, 2004.

[27] K. Sharma and F. N. Ziyadeh, "Biochemical events and cytokine
interactions linking glucose metabolism to the development of
diabetic nephropathy," *Seminars in Nephrology*, vol. 17, no. 2, pp.
80–92, 1997.

[28] M. Isono, M. C. Iglesias-De La Cruz, S. Chen, S. W. Hong, and
F. N. Ziyadeh, "Extracellular signal-regulated kinase mediates
stimulation of TGF-\(\beta1\) and matrix by high glucose in mesangial
cells," *Journal of the American Society of Nephrology*, vol. 11, no.
12, pp. 2222–2230, 2000.

[29] R. Tatsumi, H. Komaba, G. Kanai et al., "Cinacalcet induces
apoptosis in parathyroid cells in patients with secondary hyper-
parathyroidism: histological and cytological analyses," *Nephron:
Clinical Practice*, vol. 124, no. 3–4, pp. 224–231, 2013.

[30] S. V. Griffin, A. T. Petermann, R. V. Durvasula, and S. J. Shank-
land, "Podocyte proliferation and differentiation in glomerular
disease: role of cell-cycle regulatory proteins," *Nephrology Dial-
ysis Transplantation*, vol. 18, supplement 6, pp. vi8–vi13, 2003.

[31] A. Hartner, K. F. Hilgers, M. Bitzer, R. Veelken, and H. O.
Schöcklmann, "Dynamic expression patterns of transforming
growth factor-\(\beta2\) and transforming growth factor-\(\beta\) recep-
tors in experimental glomerulonephritis," *Journal of Molecular
Medicine*, vol. 81, no. 1, pp. 32–42, 2003.

[32] I. Tossidou and M. Schiffer, "TGF-\(\beta\)/BMP pathways and the
podocyte," *Seminars in Nephrology*, vol. 32, no. 4, pp. 368–376,
2012.

[33] H. S. Lee and C. Y. Song, "Effects of TGF-\(\beta\) on podocyte growth
and disease progression in proliferative podocytopathies," *Kid-
ney and Blood Pressure Research*, vol. 33, no. 1, pp. 24–29, 2010.

[34] K. Susztak, A. C. Raff, M. Schiffer, and E. P. Böttinger, "Glucose-
induced reactive oxygen species cause apoptosis of podocytes
and podocyte depletion at the onset of diabetic nephropathy," *Diabetes*,
vol. 55, no. 1, pp. 225–233, 2006.

[35] S. Jain, L. De Petris, M. Hoshi, S. Akilesh, R. Chatterjee, and
H. Liapis, "Expression profiles of podocytes exposed to high
glucose reveal new insights into early diabetic glomerulopathy," *Laboratory Investigation*, vol. 91, no. 4, pp. 488–498, 2011.

[36] C. G. Economou, P. V. Kitsiou, A. K. Trinia et al., "Enhanced
podocalyxin expression alters the structure of podocyte basal
surface," *Journal of Cell Science*, vol. 117, no. 15, pp. 3281–3294,
2004.